Sancho Juan-Manuel, Deben Guillermo, Parker Anne, Piñana José-Luis, Bolam Simon, Sánchez-García Eva, Giménez Eugenio, Pascual Teresa, Fernández-Abellán Pascual, Palomera Luis, Ribera Josep-Maria
Hematology Department, Institut Catalá d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain PETHEMA Group, Spanish Society of Hematology, Spain.
Int J Hematol. 2007 Jul;86(1):33-6. doi: 10.1532/IJH97.E0704.
Intrathecal (IT) depot liposomal cytarabine is useful in solid tumors or lymphomatous meningitis, but has scarcely been used in central nervous system (CNS) involvement in acute leukemia. We report the results of compassionate therapy with IT depot liposomal cytarabine in 10 patients with acute myeloid leukemia with CNS involvement. Five of 6 cases receiving this drug as the only IT therapy and the remaining 4 receiving it as adjuvant therapy to other CNS-directed therapies showed clearance of cerebrospinal fluid blast cells, with sustained response in 5 and mild side effects. Systemic therapy was given concomitantly in all cases, with high-dose cytarabine in 6. Clinical trials should establish the role of IT liposomal cytarabine in leukemic meningitis.
鞘内注射(IT)长效脂质体阿糖胞苷对实体瘤或淋巴瘤性脑膜炎有效,但在急性白血病累及中枢神经系统(CNS)时很少使用。我们报告了10例累及CNS的急性髓性白血病患者接受IT长效脂质体阿糖胞苷同情治疗的结果。6例将该药物作为唯一IT治疗的患者中有5例,其余4例将其作为其他CNS定向治疗的辅助治疗,结果显示脑脊液原始细胞清除,5例持续缓解,且副作用轻微。所有病例均同时进行全身治疗,6例使用大剂量阿糖胞苷。临床试验应确定IT脂质体阿糖胞苷在白血病性脑膜炎中的作用。